Risk of giant cell arteritis and polymyalgia rheumatica following COVID-19 vaccination: a global pharmacovigilance study

C Mettler, AP Jonville-Bera, A Grandvuillemin… - …, 2022 - academic.oup.com
DEAR EDITOR, COVID-19 vaccines rely on next-generation vaccine platforms of which
safety profiles are, to date, not well characterized. Sporadic cases of GCA secondary to …
被引用次数：50 相关文章
[PDF] mpg.es

[PDF][PDF] Risk of giant cell arteritis and polymyalgia rheumatica following COVID-19 vaccination: a global pharmacovigilance study

C Mettler, AP Jonville-Bera… - Rheumatology …, 2022 - mpgjournal.mpg.es
Riesgo de arteritis de células gigantes y polimialgia reumática tras vacunación con COVID-19
Page 1 Riesgo de arteritis de células gigantes y polimialgia reumática tras vacunación con …

[引用][C] Risk of giant cell arteritis and polymyalgia rheumatica following COVID-19 vaccination: a global pharmacovigilance study

C Mettler, AP Jonville-Bera, A Grandvuillemin… - Rheumatology, 2021 - cir.nii.ac.jp
Risk of giant cell arteritis and polymyalgia rheumatica following COVID-19 vaccination: a
global pharmacovigilance study | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ …

[引用][C] Risk of giant cell arteritis and polymyalgia rheumatica following COVID-19 vaccination: a global pharmacovigilance study

C Mettler, AP Jonville-Bera… - Rheumatology …, 2022 - pubmed.ncbi.nlm.nih.gov
Risk of giant cell arteritis and polymyalgia rheumatica following COVID-19 vaccination: a global
pharmacovigilance study Risk of giant cell arteritis and polymyalgia rheumatica following …

Risk of giant cell arteritis and polymyalgia rheumatica following COVID-19 vaccination: a global pharmacovigilance study

C Mettler, AP Jonville-Bera, A Grandvuillemin… - …, 2022 - academic.oup.com
DEAR EDITOR, COVID-19 vaccines rely on next-generation vaccine platforms of which
safety profiles are, to date, not well characterized. Sporadic cases of GCA secondary to …
[PDF] archive.org

[PDF][PDF] Risk of giant cell arteritis and polymyalgia rheumatica following COVID-19 vaccination: a global pharmacovigilance study

C Mettler, AP Jonville-Bera, A Grandvuillemin… - 2021 - scholar.archive.org
Risk of giant cell arteritis and polymyalgia rheumatica following COVID-19 vaccination: a
global pharmacovigilance study Camille Page 1 Risk of giant cell arteritis and polymyalgia …

[引用][C] Risk of giant cell arteritis and polymyalgia rheumatica following COVID-19 vaccination: a global pharmacovigilance study.

C Mettler, AP Jonville-Bera… - Rheumatology …, 2022 - europepmc.org
A comment on this article appears in" Comment on: Risk of giant cell arteritis and
polymyalgia rheumatica following COVID-19 vaccination: a global pharmacovigilance study …

Risk of giant cell arteritis and polymyalgia rheumatica following COVID-19 vaccination: a global pharmacovigilance study.

C Mettler, AP Jonville-Bera, A Grandvuillemin… - …, 2022 - search.ebscohost.com
The article discusses a global pharmacovigilance study on the risk of giant cell arteritis
(GCA) and polymyalgia rheumatica (PMR) following COVID-19 vaccination. Topics covered …